COVID-19 pandemic and allergen immunotherapy-an EAACI survey.
Oliver PfaarIoana AgacheMatteo BoniniHelen Annaruth BroughTomás ChivatoStefano R Del GiaccoRadoslaw GawlikAslı GelincikKarin Hoffmann SommergruberMarek JutelLudger KlimekEdward F KnolAntti LauermaMarkus OllertCorina M BersetCharlotte Gotthard MortzÓscar PalomaresCarmen RiggioniJürgen SchwarzeIsabel J SkypalaTorres María JoséEva UntersmayrJolanta Walusiak-SkorupaAdam ChakerMattia GiovanniniEnrico HefflerErika Jensen-JarolimCristina QuecchiaMónica Sandoval-RuballosÜmit Murat ŞahinerVesna Tomić SpirićMontserrat Álvaro-LozanoPublished in: Allergy (2021)
This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.